261 related articles for article (PubMed ID: 21971335)
1. Anti-interleukin-5 antibody therapy in asthma and allergies.
Corren J
Curr Opin Allergy Clin Immunol; 2011 Dec; 11(6):565-70. PubMed ID: 21971335
[TBL] [Abstract][Full Text] [Related]
2. Anti-interleukin-5 antibody therapy in eosinophilic diseases.
Simon D; Braathen LR; Simon HU
Pathobiology; 2005; 72(6):287-92. PubMed ID: 16582580
[TBL] [Abstract][Full Text] [Related]
3. Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor.
Molfino NA; Gossage D; Kolbeck R; Parker JM; Geba GP
Clin Exp Allergy; 2012 May; 42(5):712-37. PubMed ID: 22092535
[TBL] [Abstract][Full Text] [Related]
4. A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma.
Busse WW; Ring J; Huss-Marp J; Kahn JE
J Allergy Clin Immunol; 2010 Apr; 125(4):803-13. PubMed ID: 20371394
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of interleukin-5 for the treatment of eosinophilic diseases.
Corren J
Discov Med; 2012 Apr; 13(71):305-12. PubMed ID: 22541618
[TBL] [Abstract][Full Text] [Related]
6. [Anti-interleukin-5 therapy for eosinophilic diseases].
Simon D; Braathen LR; Simon HU
Hautarzt; 2007 Feb; 58(2):122, 124-7. PubMed ID: 17221241
[TBL] [Abstract][Full Text] [Related]
7. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563.
Drugs R D; 2008; 9(2):125-30. PubMed ID: 18298130
[TBL] [Abstract][Full Text] [Related]
8. The trials and tribulations of IL-5, eosinophils, and allergic asthma.
O'Byrne PM; Inman MD; Parameswaran K
J Allergy Clin Immunol; 2001 Oct; 108(4):503-8. PubMed ID: 11590372
[TBL] [Abstract][Full Text] [Related]
9. Functional CD137 receptors are expressed by eosinophils from patients with IgE-mediated allergic responses but not by eosinophils from patients with non-IgE-mediated eosinophilic disorders.
Heinisch IV; Bizer C; Volgger W; Simon HU
J Allergy Clin Immunol; 2001 Jul; 108(1):21-8. PubMed ID: 11447378
[TBL] [Abstract][Full Text] [Related]
10. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis.
Assa'ad AH; Gupta SK; Collins MH; Thomson M; Heath AT; Smith DA; Perschy TL; Jurgensen CH; Ortega HG; Aceves SS
Gastroenterology; 2011 Nov; 141(5):1593-604. PubMed ID: 21835135
[TBL] [Abstract][Full Text] [Related]
11. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys.
Hart TK; Cook RM; Zia-Amirhosseini P; Minthorn E; Sellers TS; Maleeff BE; Eustis S; Schwartz LW; Tsui P; Appelbaum ER; Martin EC; Bugelski PJ; Herzyk DJ
J Allergy Clin Immunol; 2001 Aug; 108(2):250-7. PubMed ID: 11496242
[TBL] [Abstract][Full Text] [Related]
12. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
Hilvering B; Xue L; Pavord ID
Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
[TBL] [Abstract][Full Text] [Related]
13. Subclinical phenotypes of asthma.
Bradding P; Green RH
Curr Opin Allergy Clin Immunol; 2010 Feb; 10(1):54-9. PubMed ID: 19907311
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic strategies for harnessing human eosinophils in allergic inflammation, hypereosinophilic disorders, and cancer.
Amini-Vaughan ZJ; Martinez-Moczygemba M; Huston DP
Curr Allergy Asthma Rep; 2012 Oct; 12(5):402-12. PubMed ID: 22875242
[TBL] [Abstract][Full Text] [Related]
15. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia.
Nair P; Pizzichini MM; Kjarsgaard M; Inman MD; Efthimiadis A; Pizzichini E; Hargreave FE; O'Byrne PM
N Engl J Med; 2009 Mar; 360(10):985-93. PubMed ID: 19264687
[TBL] [Abstract][Full Text] [Related]
16. [Eosinophilia and interleukin-5: role in pulmonary atopic processes].
Druilhe A; Pretolani M
Med Trop (Mars); 1998; 58(4 Suppl):437-43. PubMed ID: 10410362
[TBL] [Abstract][Full Text] [Related]
17. Mepolizumab and eosinophil-mediated disease.
Walsh GM
Curr Med Chem; 2009; 16(36):4774-8. PubMed ID: 19929788
[TBL] [Abstract][Full Text] [Related]
18. Interleukin 5 in the link between the innate and acquired immune response.
Takatsu K; Kouro T; Nagai Y
Adv Immunol; 2009; 101():191-236. PubMed ID: 19231596
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of interleukin-5 with a monoclonal antibody attenuates allergic inflammation.
Danzig M; Cuss F
Allergy; 1997 Aug; 52(8):787-94. PubMed ID: 9284977
[TBL] [Abstract][Full Text] [Related]
20. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes.
Garrett JK; Jameson SC; Thomson B; Collins MH; Wagoner LE; Freese DK; Beck LA; Boyce JA; Filipovich AH; Villanueva JM; Sutton SA; Assa'ad AH; Rothenberg ME
J Allergy Clin Immunol; 2004 Jan; 113(1):115-9. PubMed ID: 14699394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]